This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, C. Articles by Nakamura, Y. Search for Related Content PubMed PubMed Citation Articles by Suzuki, C. Articles by Nakamura, Y.

ANLN Plays a Critical Role in Human Lung Carcinogenesis through the Activation of RHOA and by Involvement in the Phosphoinositide 3-Kinase/AKT Pathway

¹ Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo; ² Department of Surgical Pathology, Hokkaido University Graduate School of Medicine, Sapporo; and ³ Kanagawa Cancer Center Research Institute, Kanagawa, Japan

Requests for reprints: Yusuke Nakamura, Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Phone: 81-3-5449-5372, Fax: 81-3-5449-5433; E-mail: yusuke{at}ims.u-tokyo.ac.jp.

Gene expression profile analysis of non–small cell lung cancers (NSCLC) and subsequent functional analyses revealed that human ANLN, a homologue of anillin, an actin-binding protein in Drosophila, was transactivated in lung cancer cells and seemed to play a significant role in pulmonary carcinogenesis. Induction of small interfering RNAs against ANLN in NSCLC cells suppressed its expression and resulted in growth suppression; moreover, treatment with small interfering RNA yielded cells with larger morphology and multiple nuclei, which subsequently died. On the other hand, induction of exogenous expression of ANLN enhanced the migrating ability of mammalian cells by interacting with RHOA, a small guanosine triphosphatase, and inducing actin stress fibers. Interestingly, inhibition of phosphoinositide 3-kinase/AKT activity in NSCLC cells decreased the stability of ANLN and caused a reduction of the nuclear ANLN level. Immunohistochemical staining of nuclear ANLN on lung cancer tissue microarrays was associated with the poor survival of NSCLC patients, indicating that this molecule might serve as a prognostic indicator. Our data imply that up-regulation of ANLN is a common feature of the carcinogenetic process in lung tissue, and suggests that selective suppression of ANLN could be a promising approach for developing a new strategy to treat lung cancers. (Cancer Res 2005; 65(24): 11314-25)

This article has been cited by other articles:

				N. Sato, J. Koinuma, M. Fujita, M. Hosokawa, T. Ito, E. Tsuchiya, S. Kondo, Y. Nakamura, and Y. Daigo Activation of WD Repeat and High-Mobility Group Box DNA Binding Protein 1 in Pulmonary and Esophageal Carcinogenesis Clin. Cancer Res., January 1, 2010; 16(1): 226 - 239. [Abstract] [Full Text] [PDF]

				A. Takano, N. Ishikawa, R. Nishino, K. Masuda, W. Yasui, K. Inai, H. Nishimura, H. Ito, H. Nakayama, Y. Miyagi, et al. Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer Cancer Res., August 15, 2009; 69(16): 6694 - 6703. [Abstract] [Full Text] [PDF]

				P. Paolo D'Avino How to scaffold the contractile ring for a safe cytokinesis - lessons from Anillin-related proteins J. Cell Sci., April 15, 2009; 122(8): 1071 - 1079. [Abstract] [Full Text] [PDF]

				D. Hirata, T. Yamabuki, D. Miki, T. Ito, E. Tsuchiya, M. Fujita, M. Hosokawa, K. Chayama, Y. Nakamura, and Y. Daigo Involvement of Epithelial Cell Transforming Sequence-2 Oncoantigen in Lung and Esophageal Cancer Progression Clin. Cancer Res., January 1, 2009; 15(1): 256 - 266. [Abstract] [Full Text] [PDF]

				T. Kato, N. Sato, A. Takano, M. Miyamoto, H. Nishimura, E. Tsuchiya, S. Kondo, Y. Nakamura, and Y. Daigo Activation of Placenta-Specific Transcription Factor Distal-less Homeobox 5 Predicts Clinical Outcome in Primary Lung Cancer Patients Clin. Cancer Res., April 15, 2008; 14(8): 2363 - 2370. [Abstract] [Full Text] [PDF]

				G. R.X. Hickson and P. H. O'Farrell Rho-dependent control of anillin behavior during cytokinesis J. Cell Biol., January 28, 2008; 180(2): 285 - 294. [Abstract] [Full Text] [PDF]

				N. Ishikawa, A. Takano, W. Yasui, K. Inai, H. Nishimura, H. Ito, Y. Miyagi, H. Nakayama, M. Fujita, M. Hosokawa, et al. Cancer-Testis Antigen Lymphocyte Antigen 6 Complex Locus K Is a Serologic Biomarker and a Therapeutic Target for Lung and Esophageal Carcinomas Cancer Res., December 15, 2007; 67(24): 11601 - 11611. [Abstract] [Full Text] [PDF]

				M. Taniwaki, A. Takano, N. Ishikawa, W. Yasui, K. Inai, H. Nishimura, E. Tsuchiya, N. Kohno, Y. Nakamura, and Y. Daigo Activation of KIF4A as a Prognostic Biomarker and Therapeutic Target for Lung Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6624 - 6631. [Abstract] [Full Text] [PDF]

				K. Tamura, M. Furihata, T. Tsunoda, S. Ashida, R. Takata, W. Obara, H. Yoshioka, Y. Daigo, Y. Nasu, H. Kumon, et al. Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-Wide Gene Expression Profiles Cancer Res., June 1, 2007; 67(11): 5117 - 5125. [Abstract] [Full Text] [PDF]

				S. Hayama, Y. Daigo, T. Yamabuki, D. Hirata, T. Kato, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, and Y. Nakamura Phosphorylation and Activation of Cell Division Cycle Associated 8 by Aurora Kinase B Plays a Significant Role in Human Lung Carcinogenesis Cancer Res., May 1, 2007; 67(9): 4113 - 4122. [Abstract] [Full Text] [PDF]

				T. Yamabuki, A. Takano, S. Hayama, N. Ishikawa, T. Kato, M. Miyamoto, T. Ito, H. Ito, Y. Miyagi, H. Nakayama, et al. Dikkopf-1 as a Novel Serologic and Prognostic Biomarker for Lung and Esophageal Carcinomas Cancer Res., March 15, 2007; 67(6): 2517 - 2525. [Abstract] [Full Text] [PDF]

				C. Suzuki, K. Takahashi, S. Hayama, N. Ishikawa, T. Kato, T. Ito, E. Tsuchiya, Y. Nakamura, and Y. Daigo Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer Mol. Cancer Ther., February 1, 2007; 6(2): 542 - 551. [Abstract] [Full Text] [PDF]

				T. Kato, S. Hayama, T. Yamabuki, N. Ishikawa, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, Y. Nakamura, and Y. Daigo Increased Expression of Insulin-like Growth Factor-II Messenger RNA-Binding Protein 1 Is Associated with Tumor Progression in Patients with Lung Cancer Clin. Cancer Res., January 15, 2007; 13(2): 434 - 442. [Abstract] [Full Text] [PDF]

				S. Hayama, Y. Daigo, T. Kato, N. Ishikawa, T. Yamabuki, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, and Y. Nakamura Activation of CDCA1-KNTC2, Members of Centromere Protein Complex, Involved in Pulmonary Carcinogenesis Cancer Res., November 1, 2006; 66(21): 10339 - 10348. [Abstract] [Full Text] [PDF]

				K. Takahashi, C. Furukawa, A. Takano, N. Ishikawa, T. Kato, S. Hayama, C. Suzuki, W. Yasui, K. Inai, S. Sone, et al. The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer Cancer Res., October 1, 2006; 66(19): 9408 - 9419. [Abstract] [Full Text] [PDF]